COMMUNIQUÉS West-GlobeNewswire

Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study

15/06/2018 - 13:50

Study completion and submission of 510(k) notification expected in Calendar Q3 2018 FRAMINGHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of [...]

Summit Therapeutics to Present at the JMP Securities Life Sciences Conference

15/06/2018 - 13:01

Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics to Present at the JMP Securities Life Sciences Conference Oxford, UK, and Cambridge, MA, US, 15 June 2018 - Summit Therapeutics plc (NASDAQ: SMMT [...]

AMAG Pharmaceuticals Announces Divestiture of Cord Blood Registry®

15/06/2018 - 13:00

Transaction Underscores AMAG’s Focus on Clinical Development and Commercialization of Pharmaceuticals Company Intends to Use the Majority of Proceeds to Pay off High-Yield Debt WALTHAM, Mass., June 15, 2018 (GLOBE [...]

Aclaris Therapeutics Expands Leadership Team, Appointing Dr. David Gordon as Chief Medical Officer

15/06/2018 - 13:00

Former Deputy Office Director at the FDA, Elaine Morefield, PhD, also joins Aclaris WAYNE, Pa., June 15, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company [...]

Summit Therapeutics to Present at the JMP Securities Life Sciences Conference

15/06/2018 - 13:00

Oxford, June 15, 2018 (GLOBE NEWSWIRE) -- Oxford, UK, and Cambridge, MA, US, 15 June 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Glyn Edwards, Chief Executive Officer, will present at the JMP [...]

Athenex Announces Appointment to Board of Directors

15/06/2018 - 13:00

BUFFALO, N.Y., June 15, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]

Trillium Therapeutics Completes Amendment to SIRPaFc License Agreement

15/06/2018 - 13:00

Trillium to issue C$3 million of common shares to retire sublicense revenue sharing provision TORONTO, June 15, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno- [...]

PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company

15/06/2018 - 12:26

Oslo (Norway), 15 June 2018 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company [...]

Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association (EHA)

15/06/2018 - 11:30

Consistently High Responses in Patients with an EZH2 Activating Mutation Durable Clinical Responses and Progression-Free Survival Observed in Patients With or Without an EZH2 Activating Mutation Company to Host Investor [...]

Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018

15/06/2018 - 11:30

3-month Phase 2 data continue to show SEL-212 (SVP-Rapamycin + pegsiticase) may present a superior product profile over current FDA-approved chronic severe gout therapy with serum uric acid (SUA) control of 81%, reduced [...]

Affimed Announces Updated Data of AFM13 in Combination with Keytruda® (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA

15/06/2018 - 11:00

Best response data from 18 patients confirms favorable safety profile and overall response rate of 89% Management to host conference call today at 8:30 a.m. ET / 2:30 p.m. CET to discuss future development plans for [...]

Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life

15/06/2018 - 08:41

Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of patients reported fatigue as [...]

Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer

15/06/2018 - 08:36

Comparison of Jakavi ® (ruxolitinib) vs. best available therapy presented at EHA suggests reduced risk of death in patients with inadequately controlled polycythemia vera (PV)[1] Additional data at EHA suggests earlier [...]

GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European Hematology Association (EHA) Congress

15/06/2018 - 08:30

Data from Four Additional Posters to be Presented, Including New Pharmacokinetic Data from HOPE-KIDS 1 Study Supporting Use of Weight-based Dosing Strategy for Voxelotor Clinical Trials in Children SOUTH SAN FRANCISCO, [...]

Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas

15/06/2018 - 08:30

Findings presented at 23rd Congress of European Hematology Association Tab-cel™ demonstrated durable remissions and encouraging safety profile in patients with EBV+ PTLD who failed first line therapy Median survival in [...]

Shire plc : Rule 2.9 Announcement

15/06/2018 - 08:01

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 15 June 2018 Shire [...]

BeiGene Provides Development Update and Presents Clinical Data on Zanubrutinib at the 23rd Congress of the European Hematology Association

15/06/2018 - 08:00

Investor Call Scheduled Today, June 15, 2018, at 8:00 am EDT CAMBRIDGE, Mass. and BEIJING, China, June 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on [...]

ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018

15/06/2018 - 07:30

LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances [...]

Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis

15/06/2018 - 07:16

Zessly ® (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly[1] Switching from the reference medicine to Erelzi [...]